Centessa \u2060Pharmaceuticals<\/a> \u200cin \u2060a deal valued at up to $7.8 billion as the U.S. \u200bdrugmaker looks \u200bto diversify beyond \u200bits metabolic portfolio and expand into treatments for sleep disorders.<\/p>\nUK-based Centessa is developing treatments for \u2060excessive daytime \u200csleepiness and other neurological \u2060conditions. Its lead therapy is currently in mid-stage studies for narcolepsy or excessive daytime sleepiness.<\/p>\n
Lilly has offered $38 per share \u200cin cash, a premium of 37.8% to Centessa’s U.S.-listed stock’s last close. \u200bCentessa’s U.S.-listed shares jumped 46% in premarket trading.<\/p>\n
Lilly has also offered one non-transferable contingent value right (CVR) of about $9 per share, \u2060or worth about $1.5 billion.<\/p>\n
Centessa’s pipeline includes additional \u200cclinical and preclinical-stage treatments with potential \u200cto treat a broader range of neurological and neuropsychiatric conditions, the companies said.<\/p>\n
The deal is expected \u2060to close in the third quarter.<\/p>\n
Eli Lilly, which \u2060touched a trillion-dollar valuation \u2060last year on the success of its blockbuster weight-loss treatments, has been making sizable \u200binvestments to bolster \u200cother parts of its pipeline.<\/p>\n
This year, the company has spent $2.4 billion to acquire Orna Therapeutics to expand its next-generation cell therapy capabilities, and more than $1 \u200bbillion to buy autoimmune \u200cdrug developer Ventyx Biosciences.<\/p>\n
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly and Company\u2019s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…\n","protected":false},"author":2,"featured_media":267186,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[552,138,553,188563,548,134,551,527,111,139,69],"class_list":{"0":"post-356798","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-biotech-and-pharmaceuticals","9":"tag-business","10":"tag-business-news","11":"tag-centessa-pharmaceuticals-plc","12":"tag-eli-lilly-and-co","13":"tag-health","14":"tag-health-care-industry","15":"tag-healthcare","16":"tag-new-zealand","17":"tag-newzealand","18":"tag-nz"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/356798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=356798"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/356798\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/267186"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=356798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=356798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=356798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}